The global randomized phase III SOLAR study (ClinicalTrials.gov, NCT02588261) is comparing ASP8273 with gefitinib or erlotinib as first-line treatments for advanced EGFR mutation-positive NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.